Business Wire

KCI Expands Surgical Incision Management Offering in Europe

Share

KCI, an Acelity Company, today announced the availability of two additional PREVENA™ Therapy offerings in Europe: the PREVENA DUO™ Incision Management System with PEEL & PLACE™ Dressing - 13cm and PREVENA PLUS PEEL & PLACE™ Incision Management System – 35cm. Both of the new introductions incorporate the proven clinical benefits of PREVENA™ Therapy, providing clinicians with solutions to meet the evolving needs of post-surgical incision management. PREVENA™ Therapy helps hold incision edges together and protects incisions from external infectious sources.

The PREVENA DUO™ System is the first single use negative pressure wound therapy (NPWT) system designed specifically for the simultaneous management of two closed surgical incisions, configured to help reduce post-operative complications in bilateral procedures, such as vascular harvesting, breast reconstruction and orthopedic trauma surgeries.

PREVENA PLUS PEEL & PLACE™ System – 35cm is suitable for long incisions commonly used in revision surgery, while also providing higher exudate storage capacity. The PREVENA PLUS™ System offers the proven effectiveness of negative pressure wound therapy with improved versatility, portability, and flexibility.

“Surgical site infections are an issue plaguing heath systems, clinicians and patients around the world,” said R. Andrew Eckert, Chief Executive Officer, KCI. “The ever-growing body of evidence supporting PREVENA™ Therapy continues to demonstrate its efficacy in lowering the incidence of SSIs. In line with our unwavering commitment to patients and our goal of moving healing forward, we hope that as a result of the availability of these two new products, more European patients will be able to benefit from PREVENA™ Therapy and reduce the burden of SSIs.”

“The impact surgical site infections have on patients its significant - delaying their recovery and return to work, causing financial worry and affecting their mental health,” Ron Silverman, M.D., FACS, Chief Medical Officer, KCI. “For those patients who are at increased risk of post-operative complications we need to look carefully at their care to ensure that they recover quickly and effectively. We are proud to be able to introduce the PREVENA DUO™ System and PREVENA PLUS PEEL & PLACE™ System – 35cm in Europe, helping provide clinicians with the tools needed to best serve their patients and provide quality care.”

Surgical site infections (SSIs) present a significant burden in Europe, with more than 500,000 cases in Europe each year.1 SSIs are associated with longer post-operative hospital stays, reduced patient quality of life, may necessitate additional surgical procedures, may require intensive care, and can result in higher morbidity and mortality.2 Infections, the most common surgical site complication, account for up to 20 percent of all of healthcare-associated infections and cost the NHS up to £700 million each year.3,4

Recently, the National Institute for Health and Care Excellence (NICE) published a Medtech Innovation Briefing (MIB) on PREVENA™ Incision Management System. The MIB assesses the most recent published evidence on the technology and surmises that PREVENA™ Therapy can lead to significantly reduced incision site complications in comparison to standard care dressings. Clinical specialists invited to add comment in the report also agreed that using PREVENA™ Therapy would likely lead to cost savings as a result of the reduction in surgical site complications (SSCs) and a reduced need for dressing changes.5

About PREVENA™ Incision Management System

The PREVENA™ System, launched in 2010, is the first disposable negative pressure system designed specifically for the management of closed surgical incisions. The PREVENA™ Incision Management System protects the incision from external contamination, helps hold incision edges together, removes fluid and infection materials, and delivers continuous negative pressure at -125mmHg for up to seven days.

Please refer to the PREVENA™ Incision Management System instructions for use for important limitations and safety information.

About KCI, an Acelity Company

KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing. Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.

1 https://ecdc.europa.eu/en/surgical-site-infections/facts

2 Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank H-P, Ducomble T, et al. (2016) Burden of Six Healthcare-Associated Infections on European Population Health: Estimating Incidence-Based Disability-Adjusted Life Years through a Population Prevalence-Based Modelling Study. PLoS Med 13(10): e1002150. https://doi.org/10.1371/journal.pmed.1002150

3 National Institute for Health and Care Excellence. Clinical guideline CG74. Surgical site infections: prevention and treatment. April 2019. Available at: https://www.nice.org.uk/guidance/ng125. Accessed July 15, 2019.

4 Leaper DJ, van Goor H, Reilly J et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J 2004; 1: 247–735. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1742-4801.2004.00067.x

5 National Institute for Health and Care Excellence. Prevena incision management system for closed surgical incisions. Medtech innovation briefing. 28 February 2019. Available at: https://www.nice.org.uk/advice/mib173. Accessed July 15, 2019.

Contact information

Maggie Fairchild
Corporate Communications
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com

Caleb Moore
Investor Relations
Phone: +1 (210) 255-6433
Email: caleb.moore@acelity.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Steering Committee launch ‘A New Era in Diabetes Care’ report highlighting the need to improve the quality of care for people with type 2 diabetes and renal / cardiovascular complications4.6.2020 01:01:00 CESTPress release

A new expert-led report has today been launched to help outline key challenges and inequalities in the care of type 2 diabetes mellitus (T2DM) and its associated renal and cardiovascular complications, and highlight some Calls to Action to try and address these gaps for the 53 million Europeans living with T2DM.1A New Era in Diabetes Care is a non-promotional disease awareness initiative that brings together a European Multidisciplinary Steering Committee of diabetes, nephrology and primary care experts, funded by Mundipharma International Limited. The report, authored by the Steering Committee, explores five main areas within the management of T2DM, chronic kidney disease (CKD) and cardiovascular disease (CVD): Healthcare professional and patient education on CKD and its signs Effective testing and interpretation of markers (clinical indicators) of CKD Greater understanding of the clinical management model amongst HCPs Use of shared decision-making to create an appropriate care plan f

Celltrion Healthcare showcases positive 1-year data and budget impact analysis for novel subcutaneous formulation of infliximab in patients with rheumatoid arthritis at the European E-Congress of Rheumatology 20204.6.2020 00:01:00 CESTPress release

At the European E-Congress of Rheumatology 2020 (The European League Against Rheumatism (EULAR) 2020 E-Congress),Celltrion Healthcare today showcased three sets of data relating to a subcutaneous formulation of infliximab, Remsima® SC. The first study demonstrated no impact of body mass index (BMI) on clinical response to CT-P13 SC in patients with active rheumatoid arthritis (RA).1 The post-hoc study investigated the impact of BMI on clinical response to CT-P13 SC in part 2 of a phase I/III randomised controlled trial (RCT) in 165 patients throughout a 1-year treatment period.1 Patients were categorized into 3 groups; under/normal weight (<25kg/m2), overweight (≥25kg/m2, <30kg/m2), and obesity (≥30kg/m2) based on the WHO BMI classification. The three groups received at least one full dose of CT-P13 SC (after IV induction) in the initial treatment stage before week 30. The data show that the mean change from baseline of DAS28 (CRP) (-3.3, -3.1, -3.3 at week 54), duration of low disease

euNetworks Secures Additional Growth Capital From IMCO and Stonepeak Infrastructure Partners3.6.2020 22:09:00 CESTPress release

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has secured an additional €250 million of capital from the Investment Management Corporation of Ontario (“IMCO”), an investor since 2018, alongside a new commitment from a vehicle managed by Stonepeak Infrastructure Partners. Pro forma for the capital raise, Stonepeak will continue to own a majority stake in euNetworks. The equity commitment will be allocated to fund further organic growth, M&A and other general corporate purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005861/en/ euNetworks (Photo: Business Wire) euNetworks is focused on delivering high bandwidth data centre to data centre connectivity between and within cities in Europe. The company owns and operates deep fibre networks in 17 cities and also operates a highly differentiated long haul network that spans 15 countries. euNetworks

NetApp to Acquire Spot3.6.2020 22:03:00 CESTPress release

NetApp® (NASDAQ: NTAP), the leader in cloud data services, today announced it has entered into a definitive agreement to acquire Spot, a leader in compute management and cost optimization on the public clouds, to establish leadership in Application Driven Infrastructure. Digital transformation initiatives have accelerated and remain the top business priority, especially in today’s environment, and the public clouds offer the speed and flexibility needed to navigate this new normal as companies find to new ways to work, interact and do business. However, unoptimized clouds can be costly and slow down the business transformation. To address this challenge, an Application Driven Infrastructure translates the application’s workload patterns and drives the best possible level of performance and cost for storage and compute, all done while maintaining the contracted service-level agreement (SLA) and service-level objective (SLO). Together, NetApp and Spot’s Application Driven Infrastructure

TeleSign Helps Skype Screen Robocalls with Score3.6.2020 18:00:00 CESTPress release

TeleSign today announced a new partnership with Microsoft’s Skype to screen robocalls using the flagship digital identity solution Score. By implementing Score, Skype is able to action against calls that are likely of a fraudulent origin. In this capacity Score is able to behave as an inbound spam filter while also preventing other types of communication fraud such as International Revenue Share Fraud (IRSF). Since implementing the TeleSign solution, Skype has been able to action upon over one million fraudulent calls per day. Ravish Patel, Sr. Director Digital Identity Solutions, said, “Robocalling has caused a major customer experience issue for end-users and causes severe reputational damage for communication apps and services who are unaware of the point and scale of such sophisticated attacks. By leveraging a global network consortium and Score's supervised machine learning algorithm, we are able to analyze and effectively flag fraudulent incoming calls, thereby saving money and p

Media Alert: ESG Event for Board Directors Featuring CEO of Bank of America and Founder of World Economic Forum Explores Measurement of Stakeholder Capitalism3.6.2020 17:45:00 CESTPress release

As companies continue to focus on long-term value creation in the face of economic recovery, operationalizing Environmental, Social, and Governance (ESG) will be critical. However, with no consistent metrics, disclosures or reporting frameworks, companies and board members struggle to effectively oversee risk, communicate performance, and measure shareholder and stakeholder impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005677/en/ Join a panel of global business leaders as the discuss what's next for ESG reporting. (Photo: Business Wire) Hear directly from the business leaders who are actively seeking to formalize common metrics and how board members can support initiatives for consistent ESG standards. Featuring Brian Moynihan, Chairman & CEO of Bank of America and Chair of the World Economic Forum International Business Council, and Klaus Schwab, Founder & Executive Chairman of the World Economic Forum, “Meas